An experimental vaccine for people who have multiple sclerosis has proved safe, clearing a necessary first hurdle toward regulatory approval. The results of this initial trial also suggest that the vaccine can indeed quell the self-destructive immune reaction that many scientists believe causes the disease.
Despite this early promise, the researchers caution that the findings are based on data gathered from a small group over a limited time.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.